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Increasing numbers of hepatitis E cases are being 
reported in several European countries, including Italy, 
but the burden of hepatitis E virus (HEV) infection is 
largely unknown in the latter. To gain a better under-
standing of HEV epidemiology at national level in Italy, 
we piloted a strengthened and integrated human (epi-
demiological and virological) and environmental HEV 
surveillance system between 2012 and 2016. Over the 
5-year period, 169 confirmed hepatitis E cases were 
identified, with a national annual incidence of 0.72 
cases per 1,000,000. Of 65 HEV-RNA positive samples 
of sufficient quality for molecular analysis, 66% were 
genotype HEV3, 32% HEV1 and 1% HEV4. The most fre-
quent risk factor reported by all HEV3 infected cases, 
was the consumption of undercooked pork and sau-
sage. For the environmental surveillance, 679 urban 
sewage samples were collected from 53 wastewater 
treatment plants and HEV-RNA was detected in 38/679 
of the samples. Among these, 25 (66%) were genotype 
HEV3 and the remaining were HEV1. We demonstrate 
that autochthonous transmission and environmen-
tal circulation of genotype HEV3 is adding to travel-
related HEV transmission in Italy. We recommend the 
‘One Health’ approach to integrated surveillance, and 
to include HEV-related messages within health infor-
mation campaigns focussing on food security.
Introduction
Hepatitis E is a systemic disease predominantly affect-
ing the liver and caused by infection with the hepati-
tis E virus (HEV). Although the burden of hepatitis E 
worldwide is unknown, it is estimated that one-third of 
the world population has been exposed to the virus at 
some time during their lives [1]. Each year, 20 million 
people are estimated to acquire HEV infections, with 
over 3 million developing symptomatic disease and 
almost 60,000 HEV-related deaths [2].
The global distribution of HEV has distinct epidemio-
logical patterns based on ecology and socioeconomic 
factors. In resource-poor countries, hepatitis E dis-
ease presents as large-scale waterborne epidemics 
of which a few have spread through person-to-person 
contact [2]. Conversely in the Western world, hepatitis 
E was traditionally considered a travel related disease, 
even though the perception has changed due to the 
increasing number of autochthonous cases reported 
in European Countries in recent years; at present it is 
recognised that HEV is endemic in the European Union/
European Economic Area (EU/EEA) [3]. Of the seven 
HEV genotypes known to infect humans (HEV1–4 and 
HEV7) and animals (HEV3–6), EU/EEA countries report 
mainly HEV3 autochthonous infections [4].
In Italy, viral hepatitis is a notifiable disease. However, 
the statutory surveillance system does not specifically 
collect data on HEV but more generically on viral hepa-
titis. Since 2007, to support the statutory system, the 
notification of acute HEV infection was included in the 
existing parallel enhanced surveillance system for viral 
hepatitis called SEIEVA (Integrated Epidemiological 
System for Acute Viral Hepatitis) [5] managed by the 
Italian Institute of Health (ISS). In parallel, a HEV envi-
ronmental surveillance, also managed by ISS, analyses 
urban sewage samples collected in the framework of 
a wastewater treatment plant (WTP)-based network 
throughout Italy [6].
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Between 2012–2016, motivated by the evidence of a 
Europe-wide increase in HEV reported cases [4] and 
by the lack of reliable data on HEV at national level, 
a strengthened human (epidemiological and virologi-
cal) surveillance of acute symptomatic HEV cases and 
a tentative integration with environmental HEV surveil-
lance, was implemented to gain a better understand-
ing of current HEV epidemiology in Italy. Here, we show 
results of this pilot surveillance system, with the per-
spective of establishing a well-functioning and inte-
grated HEV surveillance system.
Methods
Case definition and data collection
The present study was performed within the SEIEVA sur-
veillance [5]. One hundred and fifty-one of 189 Italian 
Local Health Units (LHU) voluntarily participate to the 
surveillance and collect demographic and epidemio-
logical information for all acute viral hepatitis, meeting 
the criteria included in the World Health Organization 
(WHO) case definition [7]. In addition from 2012 the 
participating LHU were required to enhance reporting 
of HEV cases and to collect more specific information 
on HEV risk factors (occupational and food-related 
risks) in the 6 weeks before symptom onset, through 
an additional data sheet. If HEV biomarkers were 
not available, LHU were required to report any acute 
viral hepatitis cases negative for hepatitis A, B and C 
viruses (defined as possible cases for the purpose of 
this study).
Human samples
The sera from the cases were sent to one of four ref-
erence laboratories for confirmation, including the 
National Reference Laboratory for Viral Hepatitis (ISS, 
Rome) or one of three Regional Reference Laboratories 
i.e. Lombardia (Università di Milano, Milan), Marche 
(Università Politecnica delle Marche, Ancona) and 
Lazio (Istituto Nazionale per le Malattie Infettive “L. 
Spallanzani”, Rome).
Amplicon sequencing of all positive samples was also 
performed by the reference laboratories. HEV RNA was 
extracted and amplified by nested reverse transcrip-
tion polymerase chain reaction (RT-PCR) using two sets 
of primers targeting ORF1 (172 bp) and ORF2 (348 bp) 
using a consolidated methodology [8]. Purified PCR 
amplicons were then subjected to bidirectional auto-
mated sequencing. We assembled the raw forward 
and reverse ABI files into a single consensus sequence 
using MEGA 6.06 software. We submitted all sequences 
to Basic Local Alignment Search Tool (BLAST) analysis 
for genotyping.
Figure 
Distribution of confirmed hepatitis E cases by month and year of notification, Italy, 2012–2016 (n = 169)
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Environmental samples
Urban sewage samples were collected from 53 waste-
water treatment plants from 16 of the 21 Regions in 
Italy. Wastewater samples were handled and analysed 
as previously described [6] and amplification and 
sequencing were performed, in the same way as for 
clinical samples, by extracting viral nucleic acids that 
were from chloroform-treated samples of wastewater 
and amplifying them using nested RT-PCR.
Analytical study and statistical analysis
A descriptive analysis of the data was conducted; 
continuous variables were presented as medians and 
ranges and categorical variables as percentages. The 
total percentages of reported risk factors can exceed 
100% since several mentions were possible. The inci-
dence of reported hepatitis E cases was computed 
using, as a denominator, the population residing in 
all the LHUs reporting to SEIEVA. The 95% confidence 
intervals (95% CI) of incidence rates were calculated 
assuming a Poisson distribution of observed cases.
In addition, the confirmed hepatitis E cases were com-
pared with nonA-nonE Hepatitis cases using non-par-
ametric Mann–Whitney test, for continuous variables, 
and chi-squared test (or Fisher’s exact test, when nec-
essary) for categorical variables.
In addition, a case–control study was conducted to 
estimate the strength of the association between 
HEV infection and different risk factors, using nonA-
nonE cases as the control group. In order to improve 
power, eight additional confirmed hepatitis E cases 
that arose during the first months of 2017 were added 
to the dataset. The association between HEV infection 
and the considered risk factor was estimated by odds 
ratios (ORs) and their 95% CI, adjusted using the mul-
tivariate logistic regression model; factors significantly 
associated in univariate analysis were included in the 
model. P values < 0.05 were considered as statistically 
significant.
All data were analysed by Stata Statistical Software, 
version 13.1, (StataCorp, Lakeway Drive College Station, 
Texas, United States).
Results
From 1 January 2012 to 31 December 2016, 456 of 5,057 
(9.0%) cases notified to the SEIEVA were possible hep-
atitis E cases. Of those, 293 (64.3%) were tested for 
IgM anti-HEV. Tested cases were more frequently from, 
or had travelled to, highly endemic areas. No other sta-
tistically significant differences in socio-demographic 
characteristics were observed between tested and 
non-tested possible hepatitis E cases. A total of 169 
(57.7%) confirmed hepatitis E cases and 124 (42.3%) 
nonA-nonE hepatitis cases were identified. Therefore, 
during the study period, 169 (3.3%) of all hepati-
tis cases notified to SEIEVA (5,057) were definitely 
ascribed to HEV. The Figure shows monthly distribution 
of confirmed hepatitis E cases. A mean of 2.8 cases per 
month, with no time trend, was observed. 
Since only 293 (64.3%) of 456 possible hepatitis E 
cases were tested, we calculated the national inci-
dence rate of confirmed Hepatitis E cases to be at 
least 0.72 cases per 1,000,000 inhabitants per year 
(95% CI: 0.62–0.84). Incidence rates ranged from 0.96 
per 1,000,000 (95% CI: 0.71–1.29) in 2016 to 0.47 per 
1,000,000 (95% CI: 0.29–0.71) in 2014. At a regional 
level, a significant difference in incidence was observed 
only in the Marche region (Central Italy) with 4.08 per 
1,000,000 confirmed hepatitis E cases per year (95% 
CI: 2.75–5.82) but 6.12 (95% CI: 2.80–11.6) in 2013. 
The increased incidence in 2013, could be explained by 
a concurrent outbreak involving eight cases between 
December 2013 and February 2014; the median age of 
these outbreak cases was 61 years (range 41–67) and 
all but one were male. Seven cases reported sausage 
consumption (information not available for one case), 
all were infected by genotype HEV3.
From 2012–2016, serum samples were collected from 
91/169 (53.8%) confirmed hepatitis E cases for HEV-
RNA determination of which, 73 (80.2%) were positive 
for HEV-RNA and 18 HEV-RNA were not detectable. Of 
the 73 HEV-RNA positive samples, 65 were adequate 
for the molecular analysis. Of those, 43 (66.2%) were 
genotype HEV3, 21 (32.3%) HEV1 and one (1.5%) 
HEV4 (Figure). Genotype distribution was associated 
with age, with HEV3 infected cases being older than 
Table 1
Comparison between hepatitis E and nonA-nonE cases on 
demographic characteristics, Italy, 2012–2016 (n = 301)
Demographic 
Characteristics
Hepatitis
p-value
E 
 
(n = 177)
nonA-nonE 
 
(n = 124)
n % n %
Age group (years)
    10–30 33/175 18.9 19/120 15.8
0.180
    31–45 39/175 22.3 40/120 33.3
    46–60 58/175 33.1 31/120 25.8
    61–87 45/175 25.7 31/120 25.0
Sex
    Male 139/177 78.5 75/123 61.0
0.001
    Female 38/177 21.5 48/123 39.0
Nationality
    Italian 114/166 68.7 103/122 84.4
0.002
    Non-Italian 52/166 31.3 1/1229 15.6
Geographical area of diagnosis
    North 72/170 42.4 56/124 45.2
0.155    Centre 94/170 55.3 60/124 48.4
    South/Islands 4/170 2.3 8/124 6.4
Different denominators for age group, sex, nationality 
and geographical area of diagnosis were due to missing 
information. 
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those infected by HEV1 (median age 58 and 31 years, 
respectively; p < 0.001). No significant difference in the 
clinical presentation and laboratory parameters was 
observed. All non-Italian cases except for one (n = 18) 
were infected by HEV1, the other by HEV4. Conversely, 
almost all Italian cases (37/39; 94.9%) were infected by 
HEV3, the remaining two cases were infected by HEV1.
With the inclusion of the additional eight confirmed 
hepatitis E cases that occurred in 2017, the analytical 
study of risk factors was performed on 177 confirmed 
hepatitis E cases. Of those, 139 were males (78.5%). 
The male to female ratio was 3.7:1. The median age 
was 50 years (range 16–87 years); no cases were 
reported among children. One hundred and fourteen 
cases (68.7%) were Italian, 52 non-Italian nationals 
15 (28.9%) were from Bangladesh, 11 (21.2%) from 
Pakistan and 12 (23.1%) from India. The majority of 
notified cases were diagnosed in Northern and Central 
Italy (Table 1).
Of the confirmed hepatitis E cases with available infor-
mation, 74% (101/137) presented with jaundice, 22/51 
(43%) with fever, 20/51 (39%) had an unexplained 
weight loss and 19/52 (37%) abdominal pain. No neu-
rological disorder was reported.
Almost all of the confirmed cases with available infor-
mation 150/160 (93.8%) required hospitalisation 
(median length 10 days; range: 2–51). Four cases had 
complications: fulminant hepatitis and two deaths, of 
which blood samples were not available. One case of 
fulminant hepatitis occurred in 2012 in a woman in her 
late-20s from Pakistan who subsequently underwent 
liver transplantation. The second case was observed in 
2013 in a man in his mid-60s from Italy, who recovered 
spontaneously. The two deaths occurred in 2014 in 
two Italian men in their 80s. Both had underlying liver 
cirrhosis (one HBV-related). Two HEV chronic cases, 
both infected with HEV3, were reported in 2012, one 
in a man in his early 60s from Italy with underlying 
malignant disease and haemolytic anaemia [9] and the 
other case was in an immunosuppressed Italian woman 
in her mid-60s [10].
Analytical study
Confirmed hepatitis E cases were more frequently male 
compared with nonA-nonE cases (78.5% vs 61.0%, 
respectively; p  =  0.001) and of non-Italian nationality 
(31.3% vs 15.6%, respectively; p = 0.001) (Table 1). No 
significant difference in the clinical presentation and 
laboratory parameters was observed.
The most frequently reported risk factor among con-
firmed hepatitis E cases was the consumption of 
undercooked pork (45/57; 79%), and undercooked pork 
sausages (32/52; 62%). All HEV3 infected cases, with 
available information, reported one or more of these 
risk factors. Of the 135 confirmed cases with available 
information, 64 (47%) reported shellfish consumption 
(38% ate raw shellfish), and all but three were infected 
by HEV3.
Of the 163 confirmed hepatitis E cases with available 
information, 42 (26%) reported travelling to South-
Asia during the 6 weeks before symptom onset (mainly 
India, Bangladesh and Pakistan); this exposure was 
more frequent among non-Italian nationals (n=34/49; 
69%). All these cases were infected with genotype 
HEV1 (one Italian case with a travel history to India and 
16 non-Italian cases travelling to their country of origin 
in South Asia). The HEV4 infected case was Croatian 
with a travel history to Ukraine. Blood transfusion was 
reported in one case (genotype information was not 
available).
Confirmed hepatitis E cases were significantly more 
often exposed to eating undercooked pork/sausage 
than nonA-nonE cases. Multivariate analysis showed a 
more than fourfold increased risk of hepatitis E associ-
ated with pork consumption and a threefold risk asso-
ciated with sausages consumption (Table 2).
Table 2
Comparison between hepatitis E and nonA-nonE cases by risk factors, Italy, 2012–2016 (n = 301)
Risk factors
Hepatitis
p-value (univ.) ORadj
a (95% CI)E (n = 177) nonA-nonE (n = 124)
n % n %
Travel 61/163 37.4 32/116 27.6 0.086 NA
Shellfish consumption 64/135 47.4 35/82 42.7 0.498 NA
Raw (among shellfish consumers) 21/55 38.2 6/16 37.5 0.961 NA
Berries consumption 13/94 13.8 5/22 22.7 0.299 NA
Drinking well water 15/130 11.5 3/45 6.7 0.354 NA
Pork consumption 45/57 79.0 30/61 49.2 0.001 4.6 (1.3–16.1)
Undercooked sausages consumption 32/52 61.5 16/48 33.3 0.005 2.9 (1.1–7.6)
CI: confidence interval; NA: not applicable because not inserted in the model; ORadj: adjusted odds ratio.
aAdjusted for age, sex, nationality and the respective other listed factor.
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Among the sub-group of cases with no travel history 
to endemic areas (116), the association with pork con-
sumption was 5.7 (95% CI 1.5–20.8).
HEV-RNA was detected in 38 of 679 (5.6%) raw sew-
age samples, of these, 25 were characterised as HEV3 
and 13 were HEV1. HEV was detected in nine of 16 
Regions throughout Italy: 4.5% (13/290) of samples 
were positive in Northern Regions; 7.2% (8/111 sam-
ples) in Central Regions and 6.1% (17/278) in Southern 
Regions, the difference was not statistically significant 
(p = 0.505).
Discussion
HEV infection is more widely distributed in Europe 
than previously thought and is spread across endemic 
and non-endemic areas by travel and zoonosis [3]. An 
increasing number of HEV cases are no longer occurring 
exclusively among returning travellers from endemic 
areas. Such cases are being reported more often in 
several European countries e.g. France [11], the UK [12] 
and Germany [13]. It is the converse in Switzerland, not-
withstanding a steady increase in demand for molecu-
lar testing, the proportion of positive HEV samples has 
remained roughly constant over the years from 2011 to 
2016 [14]. HEV circulation in Italy was demonstrated 
since the 1980s and sporadic autochthonous inci-
dent cases have been reported for several years [15]. 
Despite this, the real burden of HEV-related diseases is 
largely unknown in Italy.
We found that the estimated acute hepatitis E inci-
dence was very low in Italy, with more than 60% of 
confirmed cases having genotype HEV3. We observed 
no time trends over the study period (2012–2016) but 
did find notable difference in HEV incidence in Marche 
Region (Central Italy). This may indicate that HEV only 
provides a small contribution to the overall acute viral 
hepatitis burden in Italy, which is mainly sustained pri-
marily by hepatitis A virus (HAV) and hepatitis B virus 
(HBV) (48.4% and 32.2%, respectively) [SEIEVA data 
not shown]. However, the low incidence of HEV might 
also be a result of an underestimation of the true mor-
bidity, which could be due to three main reasons.
First, underestimation of HEV incidence could be the 
result of an unknown number of un-notified asymp-
tomatic/sub-clinical HEV infections. This hypothesis 
is supported by the fact that previous seroprevalence 
studies conducted in Italy showed relatively high preva-
lence rates of anti-HEV IgG antibodies ranging between 
1–10% [16,17] and more recently, a very high seropreva-
lence (49%) was observed among blood donors from 
the Abruzzo region [18]. Despite the considerable het-
erogeneity found between studies, which was mainly 
attributable to the assay employed and the geographi-
cal location, the HEV seroprevalences may suggest a 
wider circulation of HEV than clinically observed. This 
heterogeneity observed in different parts of Italy is 
consistent with other countries e.g. France, where HEV 
is highly endemic only in southern and north-eastern 
areas of the country [19]. This heterogeneity was also 
found in hepatitis E seroprevalence rates across Europe 
that range from 0.6% to 52.5% [20].
Second, underestimation of hepatitis E incidence could 
be the result of case under-ascertainment, with only 
one third of possible hepatitis E cases being tested for 
HEV infection during the study period. This underes-
timation seems to mainly affect cases with genotype 
HEV3, as possible hepatitis E cases tested were from, or 
had travelled to, HEV1-endemic areas more frequently 
than cases who were not tested. A non-homogeneous 
ascertainment of disease could, therefore, have con-
tributed to the observed geographical distribution of 
hepatitis E cases, since a different awareness of HEV 
infection among clinicians or health services could 
have led to higher or lower probabilities of samples 
being tested for HEV. Further, under-ascertainment 
could affect disproportionally regions with little or no 
diagnostic capacity for HEV. This finding is supported 
by the results from environmental surveillance that 
conversely showed no geographic difference in HEV 
distribution across Italy. A survey conducted in 2016 
(unpublished data) revealed that laboratory diagnos-
tic capacity for HEV infection is absent in almost half 
of all Italian regions. When present, different HEV IgM 
assays were used. This diagnostic capacity was prob-
ably poorer in 2009 [21].
Third, the lack of standardised serological diagnos-
tic tests and variant performance of IgM and IgG HEV 
assays may impact the diagnosis. This should be taken 
into account when considering the establishment of a 
regular national surveillance of acute infection, as it 
could lead to an underestimation of hepatitis E inci-
dence due to an unknown number of false negatives. 
However, in our study we classified confirmed hepati-
tis E cases by serological positivity, according to the 
WHO case definition [7]. Nevertheless, anti-HEV IgM 
ELISA was demonstrated to be a good screening test 
for surveillance purposes and not limited by inconsist-
ent performances of sensitivity and specificity among 
different assays [22].
Here, we found that two main risk factors for acquiring 
hepatitis E in Italy were linked to specific viral strains. 
Cases with genotype HEV1 were associated with travel 
to highly endemic areas. Whereas, non-travel related 
cases were associated with infection with genotype 
HEV3, which was locally acquired. The HEV3 cases 
were significantly older than HEV1 cases and more 
than 70% of cases reported consumption of under-
cooked pork/sausage, which is in line with the fact that 
HEV3 can be transmitted via the consumption of raw 
or undercooked meat of infected animal reservoirs (e.g. 
domestic pig, wild boar and deer) [23]. The multivariate 
analysis showed a fourfold greater risk of HEV3 infec-
tion after the consumption of undercooked pork, par-
ticularly an Italian sausage usually consumed raw. This 
association between HEV3 and undercooked pork was 
stronger when travel related cases were excluded from 
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the analysis, thus supporting that autochthonous HEV 
circulation in Italy is primarily related to food habits.
In Italy, pork is the most frequently consumed meat prod-
uct with an estimated pro capita yearly consumption of 
36.2 kg in 2015 [24]. Several Italian regions have tradi-
tional dishes based on raw/undercooked pork products 
(sausage in particular) and home-based processing of 
pork is still common in rural areas. This peculiar food 
habit could contribute to regional differences in HEV 
endemicity; a speculation supported by the outbreak 
that occurred in the Marche region linked to the con-
sumption of a locally produced raw pork liver sausage. 
In addition, seroprevalence of HEV in domestic pigs is 
relatively high in Italy, indicating an active circulation 
of the virus. A recent study found a 50% seropreva-
lence in swine from 42 farms located in north-western 
Italy [25]; all HEV strains isolated from wild boars and 
domestic pigs in Italy are HEV3 [25,26].
HEV transmission has been also described via blood 
and blood component transfusions. For this reason, 
donor screening for HEV-RNA is under serious consid-
eration in some developed countries [27,28]. In our sur-
veillance, blood transfusion was a reported risk factor 
in only one case, suggesting that transmission of HEV 
through this route might be limited in Italy.
From a clinical standpoint, findings from our study 
were in line with the usually described presentation 
of HEV3 infection, which is not associated with high 
mortality rates, like HEV1, but can cause chronic infec-
tion in immunocompromised or immunosuppressed 
patients [23,29]. We documented two fatal cases (both 
in patients with underlying chronic liver disease) and 
two immunocompromised cases (in which HEV infec-
tion became chronic) [9,10] but most cases presented 
with a mild and self-limiting disease.
A low frequency of HEV-RNA positive samples were 
found in urban wastewaters, possibly due to the low 
incidence and prevalence of HEV3 strain in humans. 
One third of all positive environmental samples were 
characterised as HEV1, indicating that HEV1 is also 
present in Italy; confirmed by the occurrence of human 
cases associated to travel to highly endemic areas. 
In contrast, non-travel related cases were all infected 
with HEV3, locally acquired, suggesting that HEV1 is 
not endemic in our country. In terms of environmen-
tal spread, HEV was detected in urban wastewaters 
collected from nine of 16 Italian regions, where clini-
cal cases occurred in all but two (one region was not 
covered by the SEIEVA surveillance). The occurrence of 
HEV in urban wastewater raises the question whether 
sewage-contaminated surface waters can also contrib-
ute to HEV endemicity in our country. Recently, HEV has 
been detected from Italian river waters that are receiv-
ing wastewater discharges [30]. Moreover, HEV strains 
have been isolated from shellfish, marine waters and 
underwater sewage discharges in Italy [31], suggesting 
the possibility of HEV transmission via the waterborne 
route.
Strengths and limitations
The study was an enhanced HEV surveillance set in the 
framework of a national surveillance system (SEIEVA) 
that covers 80% of the Italian population distributed 
throughout the country. It was performed through the 
merging and integration of different data sources of 
HEV information in Italy, providing a representative 
overview of the HEV situation across Italy. It is possible 
that the incidence of HEV was underestimated, how-
ever, as testing capacity/habits resulted in just 64% of 
possible cases tested.
Another possible limitation is due to the widespread 
consumption of pork in Italy, making the direct asso-
ciation of hepatitis E with pork consumption difficult to 
estimate precisely. To limit this possible bias, we used 
a control group (nonA-nonE) that was selected from 
the same population as the HEV affected group and 
thus were assumed to have access to the same food 
products.
To our knowledge, this is the first study to provide a 
comprehensive overview of HEV epidemiology in Italy, 
following the European Centre for Disease Prevention 
and Control (ECDC) recommendation for a common EU 
strategy to better understand case numbers and deter-
mine circulating strains of this virus [3]. The positive 
experiences during the pilot led to a consolidation and 
improvement of an integrated surveillance approach 
for HEV.
Conclusion
The observed low incidence of hepatitis E in Italy could 
be due to under-notification and under-ascertainment 
of cases. A potential solution would be to make hepa-
titis E a systematically notifiable disease in Italy, as 
this would help get a better estimate of the national 
incidence and burden. Integrated surveillance needs to 
be systematised through the improvement of case find-
ing and diagnostic capacity across all Italian regions. 
Importantly, the ‘One Health’ approach to integrated 
surveillance needs to also involve active surveillance of 
the animal sector (livestock and wildlife) and molecular 
surveillance also needs to be enhanced and standard-
ised. This would allow us to characterise and possibly 
link strains isolated from humans, animals and envi-
ronmental samples and interpret results in relation 
with epidemiological and clinical data.
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